Nicholas Boyd-Gibbins, MEng, PhD, serves as Chief Scientific Officer with expertise in cell engineering, immunotherapy, and regenerative medicine. Affiliated with University College London and Kyoto University, he specializes in autoimmune diseases, long COVID, iPSCs, cancer, genetics, and neuroscience, driving innovation in cell and gene therapies.

‌